safety, immunogenicity and duration of protection of the rts,sas02d malaria vaccine one year follow-up of a randomized controlled phase iiib trial安全、免疫原性和保护时间rts,sas02d疟疾疫苗一年随访的随机对照阶段希望审判.pdfVIP

safety, immunogenicity and duration of protection of the rts,sas02d malaria vaccine one year follow-up of a randomized controlled phase iiib trial安全、免疫原性和保护时间rts,sas02d疟疾疫苗一年随访的随机对照阶段希望审判.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
safety, immunogenicity and duration of protection of the rts,sas02d malaria vaccine one year follow-up of a randomized controlled phase iiib trial安全、免疫原性和保护时间rts,sas02d疟疾疫苗一年随访的随机对照阶段希望审判

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial Pedro Aide1,3*, John J. Aponte1,2, Montse Renom1,2, Tacilta Nhampossa1,3, Jahit Sacarlal 1,4, Inacio 1,3 1,2 ´ 1 5 5 Mandomando , Quique Bassat , Maria Nelia Manaca , Amanda Leach , Marc Lievens , Johan 5 5 6 5 5 1,2 Vekemans , Marie-Claude Dubois , Christian Loucq , W. Ripley Ballou , Joe Cohen , Pedro L. Alonso ˜ ´ 1 Centro de Investigac¸ao em Saude da Manhic¸a (CISM), Maputo, Mozambique, 2 Barcelona Centre for International Health Research, Hospital Clinic, University of ´ ´ ´ Barcelona, Barcelona, Spain, 3 Instituto Nacional de Saude, Ministerio de Saude, Maputo, Mozambique, 4 Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique, 5 Glaxo-SmithKline Biologicals, Rixensart, Belgium, 6 PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America Abstract Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants. Methods and Findings: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02D given at 10, 14 and 18 weeks of age staggered with routine immunization vaccines in 214 Mozambican infants. The study was double-blind until the young child completed 6 months of follow-up over which period vaccine efficacy against new Plasmodium

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档